Clinical Trials Logo

Lymphocytes clinical trials

View clinical trials related to Lymphocytes.

Filter by:
  • None
  • Page 1

NCT ID: NCT06047977 Not yet recruiting - Lymphocytes Clinical Trials

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Start date: October 1, 2024
Phase: Phase 1
Study type: Interventional

Part One of this study will determine the feasibility of creating Tumor-Infiltrating Lymphocyte (TIL) product prospectively from high-risk pediatric solid tumors. Part Two of this study will determine the safety of TIL therapy with lymphodepleting chemotherapy and post-TIL Interleukin-2 in high-risk pediatric solid tumors

NCT ID: NCT05506748 Completed - Mortality Clinical Trials

Association Between Preoperative HALP and Immediate Postoperative Outcomes

Start date: April 20, 2021
Phase:
Study type: Observational

Multiple inflammation-based prognostic scores have been developed for the prediction of perioperative morbidity and mortality following pancreaticoduodenectomy (PD). Preoperative "Hemoglobin, Albumin, Lymphocytes and Platelets index (HALP)" is one of the promising inflammatory markers that has emerged as a predictor of postoperative survival. To date, no study has been done with preoperative HALP to predict 30days morbidity and mortality. Is there any association between Preoperative HALP (hemoglobin, albumin, lymphocyte, and platelet) and 30 days post operative morbidity and mortality in patients undergoing Pancreaticoduodenectomy?

NCT ID: NCT03336086 Completed - Weight Loss Clinical Trials

Effect of Weight Reduction on Immunity

Start date: March 20, 2012
Phase: Phase 3
Study type: Interventional

This study included two groups of premenopausal healthy obese women. Experimental group underwent a weight loss program involved a low calorie diet plus anti-obesity drugs and moderate physical activity and control group underwent an ad libitum diet. At baseline and after a 10-15% weight loss lymphocyte subgroups were analyzed and compared between two group.

NCT ID: NCT00514982 Withdrawn - Colitis Clinical Trials

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

Start date: August 7, 2007
Phase: Phase 2
Study type: Interventional

This study will determine if medical treatment of colitis (inflammation of the colon resulting in loose bowel movements, rectal bleeding, and belly pain) that is used for other colitis conditions, such as Crohn's disease and ulcerative colitis, is safe and effective for treating colitis in patients with Hermansky-Pudlak syndrome (HPS). HPS is a hereditary disorder that causes albinism, visual impairment, and abnormal bleeding. Some patients also develop colitis, pulmonary fibrosis, and kidney disease. Patients with HPS and colitis who are 18 years of age or older may be eligible for this study. Participants receive treatment for their colitis symptoms with one or more of several study drugs, which include mesalamine (5-ASA), corticosteroids, infliximab and 6-mercaptopurine, adalimumab and tacrolimus. The drugs are added to the treatment plan one at a time to find the combination that works best for the individual patient. Patients who respond to one or more of the medications may continue treatment with that same combination for up to 6 months. Regular clinic visits are scheduled for blood tests, symptoms ratings questionnaires and periodic physical examinations and colonoscopies to measure the response to treatment and evaluate any side effects.